OBJECTIVE: To determine the prevalence, clinical implications and underlying mechanism of aspirin resistance in Chinese patients. METHODS: Platelet aggregation was determined by light transmission aggregometry (LTA) using four different inducers. Patients were divided into aspirin-resistant (AR), aspirin semi responder (ASR) and aspirin-sensitive (AS) groups, according to their LTA results. Aspirin resistance was assessed by thrombo elastography (TEG, with arachidonic acid [AA] or adenosine diphosphate as inducers), serum/urinary 11-dehydrothromboxane B 2 (11-DH-TXB 2 ) assay, platelet function analyser-100 assay and P-selectin assay. Polymorphisms in the prostaglandin endoperoxide synthase 1 (PTGS1) gene (A842G, C50T, C22T, G128A, C644A and C714A), the PTGS2 gene (G765C) and the integrin b 3 (ITGB3) gene (C196T) were examined. RESULTS: The study included 360 aspirin-treated patients and 314 healthy controls. AS patients had significantly lower levels of 11-DH-TXB 2 than AR and ASR patients, and significantly lower levels of P-selectin than AR patients. TEG-AA was more sensitive, specific and consistent than P-selectin in detecting aspirin resistance. The frequency of the PTGS2 G765C mutation was significantly higher in the AR/ASR groups versus the AS group. CONCLUSIONS: TEG-AA was more sensitive, specific and consistent than the P-selectin assay for detecting aspirin resistance, and the PTGS2 G765C mutation may be related to aspirin resistance.
Introduction
Aspirin is the antiplatelet agent most widely used for the prevention of ischaemic cardiovascular and cerebrovascular disease. It suppresses the synthesis of thromboxane A 2 (TXA 2 ), a potent vasoconstrictor and inducer of platelet aggregation that attenuates platelet recruitment and aggregation at vascular injury sites. 1 The long-term administration of aspirin to patients at high risk of cardiovascular and cerebrovascular disease results in significant decreases in the following: cardiovascular disease (including rates of myocardial infarction, stroke and death), bypass surgery rates, arterial thromboembolic events, pulmonary emboli, and deep vein thromboses. 2 Aspirin resistance involves the development of thrombotic vascular events despite aspirin treatment, and is defined as the impaired ability of aspirin to inhibit cyclo-oxygenase (COX)-1-dependent TXA 2 Clinical implications of aspirin resistance production. 3, 4 The aetiology of aspirin resistance involves diverse environmental and genetic factors including insufficient aspirin dosage, noncompliance to the prescribed drug regimen, gender, smoking, diabetes mellitus and the overproduction of COX-2 in platelets. 5, 6 Several techniques for the assessment of platelet function (aggregation) and aspirin response (resistance) have emerged in the past decade. These include light transmission aggregometry (LTA), closure time observation using a platelet function analyser (PFA), coagulation analysis by thromboelastography (TEG), and 11dehydrothromboxane B 2 (11-DH-TXB 2 ) and P-selectin assays. These techniques have variable efficacy and further studies are required to determine their value.
Polymorphisms in the prostaglandin endoperoxide synthase 1 gene (PTGS1), which encodes COX-1, have been implicated in the partial nonresponse to low-dose aspirin; 7 however, others have found no clear association between PTGS1 polymorphisms (C50T and A842G) and the development of aspirin resistance. 8, 9 The PlA1/A2 polymorphism of the glycoprotein IIIa (GPIIIa) platelet receptor is a further genetic factor contributing to biological aspirin resistance. This polymorphism is the most frequently investigated genetic mutation in this context. 10, 11 The present study was designed to investigate the prevalence, clinical implications and underlying mechanism of action of aspirin resistance in a Chinese population, including the presence of genetic polymorphisms associated with aspirin resistance.
Patients and methods

STUDY POPULATION
Consecutive patients who were attending Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, for routine health screening were recruited to this prospective, randomized, controlled, single-centre, single-blind cohort study between January 2007 and December 2009. Exclusion criteria were: (i) malignant hypertension or uncontrolled blood pressure; (ii) acute or chronic infection; (iii) cerebrovascular accident within the previous 2 months; (iv) hepatic, renal or respiratory insufficiency; (v) trauma or surgery within the previous month; (vi) gastrointestinal bleeding; and (vii) other blood diseases (e.g. leukaemia, haemophilia and aplastic anaemia). As reported previously, these conditions may have affected the outcomes of the study. 12 Patients were separated into two age-and gender-matched groups according to the presence of gerontic hypertension. Patients with gerontic hypertension (controlled below 150/90 mmHg) who were being treated with 100 mg/day aspirin orally were included in the aspirin-treatment group. The remaining subjects formed the healthy control group, and were not receiving aspirin treatment. There were no other specific inclusion criteria for the study.
The study was conducted in accordance with the Declaration of Helsinki (2004) and was approved by the Ethics Review Committees of Shanghai Jiao Tong University and Shanghai Ruijin Hospital, Shanghai, China. All participants provided written or verbal informed consent.
CLINICAL ASSESSMENTS
Patient data -including age and gender, together with history of diabetes mellitus, coronary heart disease, chronotropic incompetence and hyperlipidaemia -were collected. Routine blood tests (leucocyte, neutrophil, platelet and erythrocyte counts, Clinical implications of aspirin resistance together with haemoglobin concentrations) and other standard laboratory tests (including liver function tests, renal function tests, serum lipid profiles, and fasting and postprandial blood glucose concentrations) were also carried out.
ASPIRIN RESISTANCE TESTS
Blood samples (2 ml) were treated with 0.129 mmol/l sodium citrate as an anticoagulant and centrifuged at 2736 g for 15 min. Plasma was separated and stored at -80°C. Morning urine specimens from all subjects were collected, centrifuged at 2736 g for 15 min and stored at -80°C.
Platelet aggregation was assessed by LTA using a Chrono-Log platelet aggregometer (Chrono-Log Corp., Havertown, PA, USA), with arachidonic acid (AA), adenosine diphosphate (ADP), epinephrine (EPI; adrenaline) and collagen as inducers. Closure time was observed with a PFA-100 ® system (Siemens, Erlangen, Germany) with ADP and EPI as inducers. TEG was carried out using a TEG ® Coagulation Analyzer (Haemoscope Corp., Niles, IL, USA) with AA and ADP as inducers: the TEG-AA inhibition rate reflects the efficacy of aspirin, whereas the TEG-ADP inhibition rate reflects the efficacy of clopidogrel. 13, 14 Urine and serum levels of 11-DH-TXB 2 were measured via enzyme-linked immunosorbent assay (human II-DH-TXB 2 ELISA kits, Cayman Chemical Company, Ann Arbor, MI, USA). The percentage of P-selectin-positive cells was assessed via flow cytometry (Epics ® XL TM ; Beckman Coulter, Brea, CA, USA). Pselectin-positive cells ≥ 5% was defined as a positive sample. All of these assays were carried out as described previously. 15 -17 Aspirin-treated patients and control subjects underwent LTA tests and the aspirin treatment group was divided into three groups according to their LTA results.
Patients in the aspirin-resistant (AR) group had ≥ 20% platelet aggregation with 0.5 µmol/l AA or ≥ 70% aggregation with 10 µmol/l ADP. The aspirin semi-responder (ASR) group compared patients with ≥ 20% aggregation with 0.5 µmol/l AA or ≥ 70% aggregation with 10 µmol/l ADP. The AR and ASR groups were collectively called the nonaspirin-sensitive (NAS) group. Patients in the aspirin-sensitive (AS) group had < 20% aggregation with 0.5 µmol/l AA or < 70% aggregation with 10 µmol/l ADP.
All aspirin-treated patients were followedup for > 1 year.
REAL-TIME GENOMIC PCR
A 6 -10 ml sample of peripheral venous blood was obtained from each patient and control subject, treated with 0.129 mmol/l sodium citrate as an anticoagulant and stored at -80°C until use. Then, 2 ml of peripheral venous blood was used to extract genomic DNA using a Blood Genome DNA Extraction kit (Beijing Boling Kewei Biotechnology Co. Ltd, Beijing, China), and total DNA levels were determined using a Total DNA Extraction kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol.
Primers for the detection of PTGS1 (COX-1), PTGS2 (COX-2) and ITGB3 (integrin β 3 ; GPIIIa) polymorphisms were designed using Primer Express software, version 5.0 (Applied Biosystems, Foster City, CA, USA), and supplied by Shanghai Sangon Biotechnology, Shanghai, China (Table 1) . Real-time polymerase chain reaction (PCR) was performed and DNA levels were normalized to the glyceraldehyde 3-phosphate dehydrogenase levels of the healthy control group. Each PCR mixture consisted of 16.5 µl of double-distilled deionized water, 2.5 µl of 10 × PCR buffer, pH 8.0, 2 µl of dNTP mix (Shanghai BoCai Biotechnology Co. Ltd, Clinical implications of aspirin resistance Shanghai, China), 1.25 µl of 2 mmol/l forward and reverse primers, 1.25 µl of 50 ng/µl template DNA, and 0.25 µl 5 U/µl Taq polymerase (Takara Bio Inc., Shiga, Japan) using a thermal cycler from Bio-Rad. The cycling programme for PTGS1 A842G, C50T and C22T, PTGS2 G765C and ITGB3 C196T involved preliminary denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 62°C for 30 s and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 10 min. The cycling programme for PTGS1 G128A, C644A and C714A involved preliminary denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 10 min. Sequencing analysis of the PCR products was performed by Shanghai ShenSu Biotechnology Co. Ltd, Shanghai, China.
STATISTICAL ANALYSES
Statistical analyses were performed using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Data were presented as mean ± SD. The Student's ttest was used to compare study groups. Pearson's correlation coefficient (r) was used to analyse the correlation between platelet function and the various aspirin resistance tests. In aspirin-treated patients, consistency between the platelet aggregation and aspirin resistance tests was compared (κ-test) and sensitivity and specificity were assessed using P-selectin as a standard baseline. Logistic regression analysis was used to assess the risk factors that were associated with aspirin resistance. The Hardy-Weinberg principle was used to determine whether the PTSG1, PTSG2 and ITGB3 genotypes and allele frequencies were in equilibrium. A P value < 0.05 was considered to be statistically significant.
Results
A total of 674 participants were recruited to the study: 360 aspirin-treated patients (306 males and 54 females; age range 62 -94 Primer sequences used to study prostaglandin endoperoxide synthase 1 (PTGS1), prostaglandin endoperoxide synthase 2 (PTGS2) and integrin b 3 (ITGB3) gene polymorphisms in a Chinese population Clinical implications of aspirin resistance years); and 314 healthy controls (264 males and 50 females; age range 67 -93 years). There were no significant between-group differences in age, gender distribution, routine blood results, liver function, renal function, electrolyte or blood glucose levels (data not shown).
The results of platelet aggregation tests in the AR, ASR and AS patient groups are given in Table 2 . Patients in the AR and ASR groups had significantly higher levels of serum and urine 11-DH-TXB 2 , LTA ADP results and TEG-AA inhibitor ratios than patients in the AS group (P < 0.05; Table 2 ). Patients in the AR group also had significantly higher LTA AA results and P-selectin levels, and significantly lower PFA-100 ® C EPI CT results, than patients in the AS group; they also had significantly lower TEG-AA inhibitor ratios and significantly higher P-selectin levels than patients in the ASR group (P < 0.05 for all comparisons; Table 2 ).
In aspirin-treated patients, correlation analysis revealed a significant relationship between LTA findings (mean value of all four LTA tests) and serum and urine 11-DH-TXB 2 and P-selectin, between serum and urinary 11-DH-TXB 2 concentrations and P-selectin, and between serum and urinary 11-DH-TXB 2 concentrations (P < 0.01 for all comparisons; Table 3 ). Table 4 shows the sensitivity, specificity and κ-values for various platelet function and aspirin resistance tests compared with the P-selectin assay results; the P-selectin data were used as a standard baseline. In AR
Platelet aggregation
Control AR, aspirin resistant, ≥ 20% platelet aggregation in LTA with 0.5 µmol/l AA or ≥ 70% aggregation with 10 µmol/l ADP; ASR, aspirin semi-responder, ≥ 20% platelet aggregation in LTA with 0.5 µmol/l AA or ≥ 70% aggregation with 10 µmol/l ADP; AS, aspirin sensitive, < 20% platelet aggregation in LTA with 0.5 µmol/l AA or < 70% aggregation with 10 µmol/l ADP. LTA, light transmission aggregometry; AA, arachidonic acid; ADP, adenosine diphosphate; EPI, epinephrine (adrenaline); COL, collagen; PFA-100, platelet function analyser; C, collagen (in relation to PFA-100 ® ); CT, closure time; TEG, thromboelastography; 11-DH-TXB 2 , 11-dehydrothromboxane B 2 . patients, PFA-100 ® was significantly better than P-selectin in terms of specificity (P < 0.001). In NAS patients, the TEG-AA assay and the LTA (combined LTA data) assay were significantly better than the P-selectin assay in terms of sensitivity, specificity and consistency (all P < 0.001; Table 4 ). The results of the platelet function tests for determining aspirin resistance in the patient group are given in Table 5 . According to LTA (combined data) and TEG findings, there was a significant difference in the rate of aspirin resistance between the AS and AR groups (P < 0.05), and between the AS and ASR groups (P < 0.05). There was no statistically significant difference in the incidence of aspirin resistance between the AR and ASR groups.
Logistic regression analysis was performed to assess the risk factors associated with aspirin resistance (Table 6 ). Low-density lipoprotein (LDL) and high fasting blood 
TABLE 4: Comparison of the sensitivity, specificity and consistency (k-test) for selected platelet aggregation tests and the P-selectin assay a in 360 Chinese patients treated with aspirin (100 mg/day) Clinical implications of aspirin resistance
glucose levels were significantly associated with aspirin resistance (P = 0.047 and P = 0.038, respectively).
All 360 aspirin-treated patients were reexamined between 15 and 32 months after the completion of the study (median, 24 months). During the follow-up period, 16 a P = 0.047; b P = 0.038 (logistic regression analysis). Clinical implications of aspirin resistance All genotypes studied were in Hardy-Weinberg equilibrium. Of the eight gene polymorphisms studied (PTGS1 A842G, C22T, C50T, G128A, C644A, C714A, PTGS2 G765C and ITGB3 C196T), mutant PTGS1 G128A and C644A, and PTGS2 G765C alleles were detected (Table 7) . The frequency of the PTGS2 G765C mutant allele was significantly higher in NAS patients compared with AS patients (P < 0.05). There were no significant between-group differences in the frequency of the PTGS1 G128A and C644A mutant alleles (data not shown).
Discussion
Despite the emergence of new antiplatelet drugs in the last decade, aspirin remains the most widely used agent for the prevention of cardiovascular diseases. The long-term administration of aspirin to patients with high cardiovascular disease risk results in a 25% decrease in cardiovascular diseases (including myocardial infarction, stroke and death), a 48% decrease in bypass surgery and arterial thromboembolic events, a 67% decrease in pulmonary embolism events, and a 67% decrease in deep vein thromboses. 2 Thrombotic vascular events can develop, 18 despite aspirin treatment, and this phenomenon has been termed aspirin resistance. There is no standardized test for the detection of aspirin resistance; platelet function tests indicate a prevalence of 5.5 -60% in adults. 12,15 -17 The present study aimed to examine the prevalence of aspirin resistance in a group of 360 Chinese patients using various laboratory tests.
Light transmission aggregometry is commonly used to assess the degree of aspirin response in patients, 19 but this technique is operator-dependent, timeconsuming and too expensive to be widely applied. 20 Aspirin activity can also be assessed by measurement of the endproducts of the TXA 2 pathway, such as serum TXB 2 or urine 11-DH-TXB 2 . 7 LTA and TXB 2 /11-DH-TXB 2 levels also reflect the amount of TXA 2 derived from other sources besides platelets, such as macrophages and monocytes. 21 Urinary 11-DH-TXB 2 concentrations are affected by kidney function, but measurement of this metabolite is still commonly used for assessing aspirin resistance because of the low cost and easy application of the test. 7, 22 Previous studies have found little correlation between the results from different laboratory tests of aspirin resistance, therefore these laboratory assays need to be compared and assessed. A study of patients with stable coronary artery disease found that aspirin resistance varied according to which of six different platelet function tests were used. 23 In addition, the tests had different levels of variability, with the PFA-100 ® assay having 60% variability, and LTA having 4% variability. 23 P-selectin-positive platelets were used as a baseline standard for the comparison of different tests in the present study, and the TEG-AA assay was found to have higher sensitivity, specificity and consistency than the P-selectin assay. The rates of aspirin resistance detected by the LTA Frequency of wild-type and mutant alleles of prostaglandin endoperoxide synthase 1 (PTGS1) G128A and C644A, and prostaglandin endoperoxide synthase 2 (PTGS2) G765C in the 360 Chinese patients treated with aspirin Clinical implications of aspirin resistance and TEG assays were 5.28% and 7.22%, respectively. Urinary or serum 11-DH-TXB 2 and PFA-100 ® findings were unable to distinguish between the ASR and AS groups. Aspirin resistance (evaluated by the PFA-100 ® assay) has been implicated as a potential cause of the rare but serious thrombosis that can occur after drug-eluting stent implantation. Of the four patients studied, all showed resistance to either aspirin or clopidogrel, and two exhibited dual resistance to both platelet antiaggregation drugs. 24, 25 In one of these studies, 25 patients were followed-up for a median of 24 months, and the rate of ischaemic cardiovascular and cerebrovascular events was significantly higher in the NAS group compared with the AS group
The role of genetic variation in aspirin response has become increasingly evident over the past decade. Genetic polymorphismassociated aspirin resistance is most likely to be due to several factors, and may be amplified in the presence of other haemostatic genetic variations (such as polymorphisms of blood coagulation and fibrinolytic factors). 26 A series of five single nucleotide poly morphisms (SNPs) in the PTGS1 gene (A842G, C22T [R8W], G128A [Q41Q], C644A [G213G], and C714A [L237M]) have been shown to be associated with aspirin response, as determined by AAinduced platelet aggregation and serum TXB 2 assays. 27 A further study found that the A842G and C50T SNPs are in complete linkage disequilibrium. 28 In contrast to this, others have demonstrated no difference in SNP frequencies in patients who had a recurrent stroke while being treated with aspirin. 29 In addition, heterogeneity in the in vitro platelet responsiveness to aspirin has been shown to be independent of COX-1 or COX-2 protein levels and the presence of SNPs. 30 The PTGS2 gene is constitutively expressed in a limited cell population and is induced by the activation of several signal transduction pathways. 31 The COX-2 protein is covalently acetylated by aspirin, but this acetylation does not prevent the enzyme from oxidizing AA. The PTGS2-765C variant has been shown to result in a slightly higher reduction in 11-DH-TXB 2 levels after aspirin treatment: 32 a finding contrary to the results of others. 30 Platelet GPIIb/IIIa receptors play a basic role in platelet aggregation by binding fibrinogen and von Willebrand factor. 10 The PlA polymorphism of the ITGB3 gene modulates platelet function, with the PlA2 allele being associated with increased platelet reactivity. 33 In contrast to some studies, the PlA2 allele has been shown to be a potential risk factor associated with coronary heart disease and stent thrombosis. 33 A study has shown that PlA polymorphisms may account for some of the differences seen in aspirin and abciximabinduced antiplatelet effects. 34 The platelets of patients with intracoronary stent restenosis are more likely to be resistant to low-dose aspirin therapy, regardless of PlA2 status. 35 Mutant alleles of the PTGS1 G128A and C644A, and PTGS2 G765C polymorphisms were detected in all aspirin-treated patients in the present study, and the frequency of the PTGS2 G765C mutant allele was significantly higher in NAS patients compared with AS patients. There was, however, no betweengroup difference in the frequency of either PTGS1 mutation. As individuals carrying the PTGS2 G765C polymorphism have a higher risk of aspirin resistance compared with other individuals, selective detection of this mutation may be useful in determining clinical thrombotic disease prevention in specific patients. It is important to note that the findings may have been affected by sample bias, and the reason for aspirin In conclusion, the rate of aspirin resistance in elderly Chinese patients was approximately 5 -7%, and the TEG-AA was more sensitive, specific and consistent than the P-selectin assay for the detection of aspirin resistance. The frequency of the mutant allele of the PTGS2 G765C polymorphism may be related to aspirin resistance.
